Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing explores why particle size is critical to drug efficacy, how Oncotelic’s technology enhances tumor targeting, and how its rapid IND platform accelerates clinical development across multiple assets.
Particle Size: The Key to Targeted Drug Delivery
Delivering anticancer drugs effectively remains a central challenge in oncology. Conventional chemotherapy exposes healthy tissues to cytotoxic agents, producing severe side effects, while oral targeted therapies often fail to reach tumors at therapeutic concentrations. Nanomedicine offers a solution, but not all nanoparticles are equal. The size of a nanoparticle determines its biodistribution, cellular uptake, and ability to penetrate tumors. Oncotelic’s Deciparticle(TM) technology achieves a precise 20nm particle size, which is optimal for evading the immune system, penetrating the leaky vasculature of tumors via the enhanced permeability and retention (EPR) effect, and delivering drugs directly to cancer cells.
The importance of this precision is highlighted by comparing Sapu003 to oral Everolimus. Oral Everolimus has only about 10% bioavailability due to first-pass metabolism and poor absorption. In contrast, intravenous delivery of Sapu003 achieves full bioavailability, meaning nearly 100% of the administered dose reaches the bloodstream and can target tumors. This maximizes tumor exposure while minimizing systemic side effects. Australian HREC approval validates the safety and ethical design of the Phase 1 trial, which will assess the pharmacokinetics, safety, and preliminary efficacy of Sapu003 in patients with advanced breast cancer.
Rapid IND Platform Accelerates Pipeline
Beyond Sapu003, Oncotelic’s strategic partnership with Medicilon supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle(TM) drug candidates to reach clinical testing quickly. This rapid IND platform leverages the proprietary nanoparticle technology to reformulate existing drugs, potentially improving their therapeutic index. By standardizing the manufacturing and characterization of 20nm nanoparticles, Oncotelic can efficiently advance a pipeline of targeted therapies for various cancers.
The implications of this announcement are significant for the field of nanomedicine. If successful, Sapu003 could demonstrate that particle size engineering is a critical factor in overcoming the limitations of conventional drug delivery. The ability to achieve full bioavailability with intravenous administration could set a new standard for delivering poorly soluble or poorly absorbed drugs. Furthermore, the rapid IND platform suggests that Oncotelic can quickly translate preclinical successes into clinical trials, potentially bringing multiple nanomedicines to patients faster.
Investors and researchers should monitor the Phase 1 trial results, as they will provide crucial data on the safety and pharmacokinetics of 20nm nanoparticles in humans. The outcome could validate Oncotelic’s approach and pave the way for a new class of cancer therapies that maximize efficacy while minimizing toxicity. For more information, visit the company’s newsroom at ibn.fm/OTLC.
